Insulin aspart, recombinant Subcutaneous and Risankizumab-rzaa topical
Determining the interaction of Insulin aspart, recombinant Subcutaneous and Risankizumab-rzaa topical and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: insulin aspart
Brand name: Fiasp, NovoLog, NovoLog FlexPen, NovoLog PenFill, NovoLOG FlexTouch, Fiasp PenFill, Fiasp FlexTouch
Synonyms: Insulin aspart, Insulin Aspart
Generic Name: risankizumab
Brand name: Skyrizi
Synonyms: Risankizumab
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Insulin aspart, recombinant Subcutaneous-Risedronate
- Insulin aspart, recombinant Subcutaneous-Risedronate and Calcium
- Insulin aspart, recombinant Subcutaneous-Risedronate Delayed Release
- Insulin aspart, recombinant Subcutaneous-Risedronate Delayed-Release Tablets
- Insulin aspart, recombinant Subcutaneous-Risedronate Sodium
- Insulin aspart, recombinant Subcutaneous-Risedronate Tablets
- Risankizumab-rzaa topical-Insulin degludec
- Risankizumab-rzaa topical-Insulin Degludec (U-100) Prefilled Pens
- Risankizumab-rzaa topical-Insulin Degludec (U-100) Vials
- Risankizumab-rzaa topical-Insulin Degludec (U-200) Prefilled Pens
- Risankizumab-rzaa topical-Insulin degludec and liraglutide
- Risankizumab-rzaa topical-Insulin degludec and liraglutide Subcutaneous